Review articleInsulin glargine: A systematic review of a long-acting insulin analogue
References (77)
Intensive treatment of type 1 diabetes
Med Clin North Am.
(1998)- et al.
Insulin glargine
Lancet
(2000) - et al.
Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells
Eur J Pharmacol.
(1997) Safety of insulin glargine
Lancet
(2000)The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
N Engl J Med.
(1993)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet
(1998)The physiologic replacement of insulin. An elusive goal
N Engl J Med.
(1989)- et al.
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro
Diabetes
(2000) Physiological insulin replacement in type 1 diabetes mellitus
Exp Clin Endocrinol Diabetes
(2001)- et al.
The action profiles of human NPH insulin preparations
Diabet Med.
(1989)
Long-acting insulin analogs
Diabetes Care
(1999)
Long acting insulin analogues: Can they provide a basal insulin level?
J Pediatr Endocrinol Metab.
(1999)
Recombinant DNA technology in the treatment of diabetes: Insulin analogs
Endocr Rev.
(2001)
Rapid and long-acting analogues as an approach to improve insulin therapy: An evidence-based medicine assessment
Curr Pharm Des.
(2001)
Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin
Diabetes Care
(2001)
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
Diabetes Care
(2000)
Insulin glargine: A new basal insulin
Ann Pharmacother.
(2002)
Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
Diabetes Care
(2000)
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
Diabetes Care
(2000)
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
Diabetes Care
(2000)
A new long-acting insulin (HOE 901) demonstrates less nocturnal hypoglycemia when compared with protamine insulin in a clinical trial
Diabetologia
(1998)
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
Diabetes Care
(2000)
Insulin glargine: The first clinically useful extended-action insulin analogue
Expert Opin Pharmacother
(2001)
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
Diabet Med.
(1999)
Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans
Exp Clin Endocrinol Diabetes
(2000)
A randomized 3 period crossover trial investigating the effect of subcutaneous insulin detemir and human insulin on glucose metabolism in healthy subjects
Diabet Med.
(2001)
Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal/bolus regimen
Diabetologia
(2001)
Insulin glargine
Am J Health Syst Pharm.
(2000)
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites
Diabetes Care
(2000)
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
Diabetes Care
(2000)
Comparison of the pharmacokinetic/dynamics of Gly (A21)-Arg (B31, B32) human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycemic clamp technique
Diabetologia
(1994)
Time-action profile of insulin glargine (HOE901) in Japanese volunteers
Diabetes
(2000)
24h Profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology
Diabetes
(1997)
Pharmacodynamics of s.c. injection of the long-acting insulin glargine (HOE901) in TIDM
Diabetes
(1999)
Comparison of the sc absorption of HOE901 and NPH human insulin type 2 diabetic subjects
Diabetes
(1999)
An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and Ultralente human insulins using the euglycaemic clamp technique
Clin Pharmacol Ther.
(2000)
Insulin glargine:A review of its therapeutic use as along-acting agent for the management of type 1 and 2 diabetes mellitus
Drugs
(2001)
Cited by (117)
Recent advancements on novel approaches of insulin delivery
2023, Medicine in Novel Technology and DevicesPrevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery
2021, Advanced Drug Delivery ReviewsTowards in vitro in vivo correlation for modified release subcutaneously administered insulins
2020, European Journal of Pharmaceutical SciencesPrescription patterns and costs of antidiabetic medications in a large group of patients
2018, Primary Care Diabetes
Copyright © 2003 Published by Elsevier Inc.